Arteriocyte Inc.
This article was originally published in Start Up
Executive Summary
Arteriocyte has proprietary technology for selecting and harvesting combinations of multiple stem cell types that, when injected into the arterial system, generate new blood vessels to revascularize ischemic cardiac tissue. The company is starting out with autologous stem cells from patient's bone marrow. It intends to move quickly into products made from allogeneic cells sourced from umbilical cord blood, thus providing physicians with a standardized, off-the-shelf therapy.
You may also be interested in...
Succeeding in Heart Failure, Incrementally
Because of the heterogeneity of heart failure patients and causes, new drugs to treat heart failure haven't been a huge area of research or business development. Few heart failure drugs are likely to be blockbusters, and there are very few deals around truly novel targets. Biotech start-ups build on known approaches and innovate incrementally, in this market.
Succeeding in Heart Failure, Incrementally
Because of the heterogeneity of heart failure patients and causes, new drugs to treat heart failure haven't been a huge area of research or business development. Few heart failure drugs are likely to be blockbusters, and there are very few deals around truly novel targets. Biotech start-ups build on known approaches and innovate incrementally, in this market.
Stem Cells: What's the Business Model?
The science of stem cells is progressing, slowly but surely, towards the ultimate goal of creating a therapeutic. The challenge is now largely economic: convincing investors that stem cells present a viable business opportunity.